Off-label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center.
compassionate use
off-label
pediatric oncology
targeted therapies
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
28
10
2022
received:
08
07
2022
accepted:
21
11
2022
pubmed:
31
12
2022
medline:
27
1
2023
entrez:
30
12
2022
Statut:
ppublish
Résumé
In Europe, despite recent advances in clinical development, most of the drugs currently used to treat childhood cancers are adult medicines, prescribed outside of the authorized indication. In this context, a monocentric retrospective cohort analysis was conducted, evaluating pediatric, adolescent, and young adult patients affected by onco-hematologic disease, treated with targeted therapies used off-label or as compassionate use. The analysis was conducted on 45 patients aged less than or equal to 30 years with cancer, having received at least one targeted therapy prescribed as off-label or compassionate use at a large Italian pediatric center between January 1, 2016 and June 30, 2021. Data collected included information on the patient and tumor, data on off-label/compassionate treatment, and data on safety and efficacy. Total 25 out of 45 patients treated with off-label or compassionate targeted therapies were affected by onco-hematological diseases. Overall, 22 out of the 52 agents (42%) were prescribed in patients with relapsed neoplasm and 39% (20/52) in patients with refractory diseases. Complete response was observed in more than half (27/52) of treatments. At least one adverse reaction occurred in 76% (n = 22) of agents administered to patients with onco-hematological tumor and in 43% (n = 10) of agents prescribed to patients with solid tumor. This work aims to provide a snapshot of off-label and compassionate use prescriptions in a large Italian pediatric cancer center. This study confirms that targeted agents for unauthorized indications are often prescribed in pediatric patients with cancer, especially after disease relapse and that these treatments are mostly tolerable and effective.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30148Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol. 2013;14(3):e95-e103. doi:10.1016/S1470-2045(13)70010-X
Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):35-47. doi:10.1016/S1470-2045(13)70548-5
European Childhood Cancer Organisations’ recommendations following the European Commission's evaluation of the Legislation for Medicines for Rare Diseases and Children and the launch of the Pharmaceutical Strategy for Europe. SIOP Europe; November 1, 2020. Accessed May 26, 2022. https://siope.eu/media/documents/recommendations-following-the-european-commissions-evaluation-of-the-legislation-for-medicines-for.pdf
Pearson AD, Heenen D, Kearns PR, et al. 10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers. Lancet Oncol. 2018;19(3):285-287. doi:10.1016/S1470-2045(18)30105-0
Vassal G, Kozhaeva O, Griskjane S, et al. Access to essential anticancer medicines for children and adolescents in Europe. Ann Oncol. 2021;32(4):560-568. doi:10.1016/j.annonc.2020.12.015
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. NIH. Accessed May 26, 2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdf
Model Selection and Multimodel Inference. 2nd ed. Springer; 2002.
Grambsch PM. Goodness-of-fit and diagnostics for proportional hazards regression models. Cancer Treat Res. 1995;75:95-112. doi:10.1007/978-1-4615-2009-2_5
Vassal G, Rousseau R, Blanc P, et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur J Cancer. 2015;51(2):218-224. doi:10.1016/j.ejca.2014.10.029
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
AIEOP. Accessed May 26, 2022. https://www.aieop.org/web/
Lim M, Shulman DS, Roberts H, et al. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020;9(18):6658-6666. doi:10.1002/cam4.3349
Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251-258. doi:10.1111/jcpt.12507
MJ D, BK E, Lam CP. Off label and unlicensed prescribing in a specialist oncology center in Australia. Asia Pac J Clin Oncol. 2009;5(4):242-246.
Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1726-1736. doi:10.1158/1078-0432.CCR-09-1961
Saiyed MM, Lalwani T, Rana D. Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital. Int J Risk Saf Med. 2015;27(1):45-53. doi:10.3233/JRS-150642
Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77. doi:10.1038/s41408-020-00342-x
Carceller F, Bautista F, Castaneda A, et al. Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: an Innovative Therapies for Children with Cancer (ITCC) study. J Clin Oncol. 2019;37(15):e21509.